Complex I: inhibitors, inhibition and neurodegeneration
1Department of Clinical Neurosciences, Institute of Neurology, Rowland Hill St., London NW3 2PF, UK. a.schapira@medsch.ucl.ac.uk
Abstract:
Complex I is the first protein component of the mitochondrial respiratory chain and as such plays a crucial role in ATP production and mitochondrial function in general. Mitochondrial dysfunction has been identified in a number of neurodegenerative diseases. In some of these the mitochondrial abnormality is primary and in others secondary. Mitochondrial toxins are capable of producing relatively selective neuronal cell death and have been used to produce models of human neurodegenerative diseases e.g. 1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine (MPTP) for Parkinson's disease, and 3-nitropropionic acid for Huntington's disease. Annonacin, an ingredient of local soursop, is a Complex I inhibitor and has been incriminated as the cause of a parkinsonian tauopathy disorder in Guadeloupe. A systematic analysis has identified several environmentally available potent lipophilic Complex I inhibitors that can induce neuronal cell death in striatal cultures and somatodendritic redistribution of tau protein. It is possible that these compounds may contribute to the pathogenesis of neurodegenerative disorders, although further work must be done to confirm their potential participation in pathogenesis.
Insights
Certain environmental toxins that inhibit Complex I (the first protein in mitochondrial respiration) can cause neuronal death. These toxins may contribute to the development of neurodegenerative diseases like Parkinson's.
Area of Science:
- Neuroscience
- Biochemistry
- Toxicology
Background:
- Mitochondrial dysfunction is implicated in neurodegenerative diseases.
- Complex I is vital for ATP production and overall mitochondrial function.
- Mitochondrial toxins serve as models for neurodegenerative disease research.
Purpose of the Study:
- To identify environmental Complex I inhibitors.
- To investigate their potential role in neurodegenerative disease pathogenesis.
- To analyze their effect on neuronal cell death and tau protein redistribution.
Main Methods:
- Systematic analysis of environmentally available compounds.
- In vitro studies using striatal neuronal cultures.
- Assessment of Complex I inhibition, neuronal cell death, and tau protein changes.
Main Results:
- Identification of potent, lipophilic Complex I inhibitors from environmental sources.
- Demonstration that these inhibitors induce striatal neuronal cell death in vitro.
- Observation of somatodendritic redistribution of tau protein following inhibitor exposure.
Conclusions:
- Environmentally available Complex I inhibitors can cause neuronal damage.
- These compounds are potential contributors to neurodegenerative disease pathogenesis.
- Further research is needed to confirm their role in disease development.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:29Drugs Affecting Neurotransmitter Synthesis
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...